We are live on ! Find out more
VMI

VHCP Management III Portfolio holdings

AUM $504M
1-Year Est. Return 683.12%
This Fund
S&P 500
This Quarter Est. Return
+34.72%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$214M
AUM Growth
+$42.6M
Cap. Flow
+$32M
Cap. Flow %
14.95%
Top 10 Hldgs %
93.72%
Holding
17
New
1
Increased
4
Reduced
8
Closed
–

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$42.6M
2
AXSM icon
Axsome Therapeutics
AXSM
+$10.9M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$2.91M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$1.87M
5
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$1.73M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$12.7M
2
KALV
KalVista Pharmaceuticals
KALV
+$7.8M
3
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$2.37M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$2.15M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.12M

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
1
Milestone Pharmaceuticals
MIST
$138M
$56.1M 26.2%
+2,066,529
New +$42.6M
AXSM icon
2
Axsome Therapeutics
AXSM
$11.2B
$41.5M 19.37%
1,611,329
+543,285
+51% +$10.9M
RARX
3
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$20.2M 9.41%
670,350
+75,637
+13% +$1.73M
KALV
4
DELISTED
KalVista Pharmaceuticals
KALV
$14.1M 6.6%
637,884
-332,746
-34% -$7.8M
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$13.1M 6.12%
1,159,789
– –
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.79B
$13M 6.06%
1,072,348
+263,025
+32% +$2.91M
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
$11.6M 5.41%
1,251,898
+248,298
+25% +$1.87M
TCDA
8
DELISTED
Tricida, Inc. Common Stock
TCDA
$11.4M 5.34%
289,746
-360,839
-55% -$12.7M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.28B
$10.3M 4.79%
2,708,207
-352,884
-12% -$2.12M
ORTX
10
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$9.46M 4.42%
67,625
-13,478
-17% -$2.37M
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5.22M 2.44%
314,741
– –
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$5.8B
$4.23M 1.97%
312,320
-15,457
-5% -$240K
BLPH
13
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$1.45M 0.68%
161,148
– –
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
$870K 0.41%
422,141
-965,733
-70% -$2.15M
CNST
15
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$819K 0.38%
66,667
– –
MTVA
16
MetaVia Inc
MTVA
$7.33M
$646K 0.3%
12
-1
-8% -$73.2K
KA
17
DELISTED
Kineta, Inc. Common Stock
KA
$216K 0.1%
1,580
-3,584
-69% -$556K

Similar funds

BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return

VHCP Management III's Q2 2019 Portfolio in Review

As of Q2 2019, VHCP Management III held 17 positions worth $214M, up 25% from $172M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

VHCP Management III deployed $32M of net new capital in Q2 2019, opening 1 new position and adding to 4 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 2,066,529 shares worth $56.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Tricida, Inc. Common Stock, an estimated $12.7M trimmed.

  • VHCP Management III's largest Q2 2019 buy was Milestone Pharmaceuticals: 2,066,529 shares worth $56.1M.
  • VHCP Management III added most to Axsome Therapeutics in Q2 2019, an estimated $10.9M increase.
  • VHCP Management III's biggest Q2 2019 reduction was Tricida, Inc. Common Stock, cutting an estimated $12.7M.
  • VHCP Management III's ten largest holdings make up 94% of its $214M portfolio in Q2 2019.
  • VHCP Management III opened 1 new position and closed 0 in Q2 2019.
  • VHCP Management III's portfolio value rose 25% quarter-over-quarter to $214M.

Based on VHCP Management III's 13F filing for Q2 2019, filed 13 Aug 2019.